Combined Lumacaftor-Ivacaftor Therapy: Safe and Effective for Cystic Fibrosis Patients

In an international clinical trial, treatment with two medications, which targeted the most common genetic cause of cystic fibrosis, improved lung function.

Cystic fibrosis, a genetic disease that causes the body to create thick and sticky mucus, can now be controlled, thanks to a new breakthrough research.

In an international clinical trial, treatment with two medications, which targeted the most common genetic cause of cystic fibrosis, improved lung function and lowered the rate of pulmonary exacerbations.

Chilean Teenager With Cystic Fibrosis Who Asked for Euthanasia on YouTube Passes Away
Valentina Maureira died on May 14 due to complications from the genetic disorder, which attacks the lungs and other organs.

The Combined Lumacaftor-Ivacaftor Therapy was shown to be safe and effective for cystic fibrosis patients.

The mucus formed due to this disease leads to chronic infections and increased loss of lung function. In the pancreas, the thick mucus keeps enzymes from reaching the gut to digest food. The median life expectancy is 37 years, and available treatments mostly focus on managing symptoms and consequences of the disease.

McColly, an Associate Director at the Cystic Fibrosis Center at Lurie Children’s said, while significant progress has been made with supportive therapies for cystic fibrosis, developing treatments that address the underlying genetic cause still is a challenge.

Resistance to Anti-Viral Medication may be More Likely in Cystic Fibrosis Patients
A drug called ganciclovir is given to lung transplant patients to protect against a life-threatening virus that is common after transplantation.

The research claims that combining Ivacaftor with Lumacaftor helps patients with the most common cystic fibrosis mutation.

Potential Drug That Could Help Treat Cystic Fibrosis Identified
Researchers have discovered an inhibitor for an enzyme called Sphingomyelin phosphodiesterase C produced by the S. aureus bacterium which may harm the health of cystic fibrosis patients.

The study is published in the New England Journal of Medicine.

Source-ANI

Antibacterial Resistance a Cause for Major Concern: Cystic Fibrosis Expert
From Queen's University Belfast, world leading Cystic Fibrosis experts have called for greater research to address the major concern of antibacterial resistance.